Evidence map›Paper›PMID 23704520›Full record

ReviewDiabetes2013

Biochemical basis of the antidiabetic activity of oleanolic acid and related pentacyclic triterpenes.

Jose M Castellano, Angeles Guinda, Teresa Delgado, Mirela Rada, Jose A Cayuela

2 registry-linked trialsOpen access · hybridAbstract readReview
In one paragraph

Review in Diabetes, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 97 papers.

0numbers the graph read from it
0cells of the map it votes in
97citing papers in PubMed
9.1field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT05529953 nacompletednot on this mapstarted 2021, after this paper: background citation

Bioavailability Assays of Oleanolic Acid, Formulated as Functional Olive Oil, in Healthy Subjects. Pharmacokinetic Analysis and Study of Its Integration in Postprandial Human Triglyceride-Rich Lipoproteins

TypeinterventionalSponsorSpanish National Research CouncilRan2021 to 2021Enrolled22ConditionsHealthy Subjects, BioavailabilityArmsOleanolic acid (CAS no. 598-02-1, PubChem CID 10494), Control commercial olive oil
NCT06030544 phase2active not recruitingnot on this mapstarted 2022, after this paper: background citation

Oleanolic Acid as Therapeutic Adjuvant for Type 2 Diabetes Mellitus (OLTRAD STUDY)

TypeinterventionalSponsorSpanish National Research CouncilRan2022 to 2025Enrolled100ConditionsDiabetic Patients, Type II Diabetes MellitusArmsOA-enriched functional olive oil, commercial olive oil
3 · Its place in the literature

Who cites it

97 citing papers in PubMed, 232 citations in OpenAlex.

  1. Trial
  2. Article
  3. Review
  4. Review
  5. Article
  6. Article
  7. Review
  8. Article
  9. Review
  10. Article
  11. Chemical profile ofFrontiers in chemistry · 2025
    Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Review
  17. Identification of Phytochemicals and Assessment of Hypoglycemic and Haematological Potentials ofCardiovascular & hematological agents in medicinal chemistry · 2024
    Article
  18. Review
  19. Article
  20. Natural Compounds and Glutathione: Beyond Mere Antioxidants.Antioxidants (Basel, Switzerland) · 2023
    Review

37 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 1 country.

Jose M CastellanoInstituto de la Grasa, Consejo Superior de Investigaciones Cientificas, Seville, Spain. jmcas@ig.csic.es
Angeles Guinda
Teresa Delgado
Mirela Rada
Jose A Cayuela
Consejo Superior de Investigaciones Científicas · ESInstituto de la Grasa · ES

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Oleanolic acid (OA), a natural component of many plant food and medicinal herbs, is endowed with a wide range of pharmacological properties whose therapeutic potential has only partly been exploited until now. Throughout complex and multifactorial mechanisms, OA exerts beneficial effects against diabetes and metabolic syndrome. It improves insulin response, preserves functionality and survival of β-cells, and protects against diabetes complications. OA may directly modulate enzymes connected to insulin biosynthesis, secretion, and signaling. However, its major contributions appear to be derived from the interaction with important transduction pathways, and many of its effects are consistently related to activation of the transcription factor Nrf2. Doing that, OA induces the expression of antioxidant enzymes and phase II response genes, blocks NF-κB, and represses the polyol pathway, AGEs production, and hyperlipidemia. The management of type 2 diabetes requires an integrated approach, which includes the early intervention to prevent or delay the disease progression, and the use of therapies to control glycemia and lipidemia in its late stages. In this sense, the use of functional foods or drugs containing OA is, undoubtedly, an interesting path.

Indexed as

HumansHyperglycemiaHypoglycemic AgentsInsulin-Secreting CellsMolecular StructureOleanolic AcidPentacyclic TriterpenesHypoglycemic AgentsOleanolic AcidPentacyclic Triterpenes

Identifiers

PMID23704520
PMCPMC3661625
OpenAlexW2168624276

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.